Skip to main content
. Author manuscript; available in PMC: 2023 Jul 31.
Published in final edited form as: Sci Immunol. 2023 Jul 7;8(85):eadd4817. doi: 10.1126/sciimmunol.add4817

Figure 5. Human primary cancer cells are permissive to cDC1 reprogramming.

Figure 5

(A) Reprogramming efficiency of human primary tonsil carcinoma (JCA10), glioblastoma (G2572) and CAFs at reprogramming day 9 and (B) quantification from 35 patient samples. Reprogrammed (CD45+HLA-DR+) and partially reprogrammed populations (CD45+HLA-DR- and CD45-HLA-DR+) are shown. Individual patients are depicted by codes (n=2-6). Mean±SD is represented. (C) Reprogrammed and partially reprogrammed cells from 27 human primary tumor samples were purified and profiled by scRNA-seq without multiplexing. Peripheral blood cDC1 were used as reference, and eGFP-transduced cells as controls. UMAP analysis of single-cell transcriptomes showing 136,796 primary cancer cells according to their origin (upper panel) or treatment (bottom panel). (D) UMAP plots showing expression of cDC1 genes ZNF366 and C1ORF54, reprogramming markers PTPRC and HLA-DRA, endogenous expression of IRF8 and BATF3, costimulatory molecule CD40, and tumor-APC signature. (E) Integration of single-cell data from a reprogramming time-course of the T98G cell line (left) and primary tumor samples (right) with published DC subset data (GSE94820). Heatmap shows the percentage of single cells affiliated to individual cDC subsets or unaffiliated (U/A). (F) UMAP showing single-cell transcriptomes of cDC1-affiliated cells.